Meyka Pro banner
Autonomix Medical, Inc.

Autonomix Medical, Inc. Fundamental Analysis (NASDAQ: AMIX)

AMIXNASDAQ
HealthcareMedical - Devices
$4.57
$1.82(66.18%)
U.S. Market opens in 16h 37m

Autonomix Medical, Inc. Fundamental Analysis (NASDAQ: AMIX)

Autonomix Medical, Inc. (NASDAQ: AMIX) shows weak financial fundamentals with a PE ratio of -0.04, profit margin of 0.00%, and ROE of -2.39%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position282.09%
PEG Ratio-0.00
Current Ratio4.45

Areas of Concern

ROE-2.39%
Operating Margin0.00%
We analyze AMIX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -300.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-300.2/100

We analyze AMIX's fundamental strength across five key dimensions:

Efficiency Score

Weak

AMIX struggles to generate sufficient returns from assets.

ROA > 10%
-2.20%

Valuation Score

Excellent

AMIX trades at attractive valuation levels.

PE < 25
-0.04
PEG Ratio < 2
-0.00

Growth Score

Weak

AMIX faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

AMIX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
4.45

Profitability Score

Weak

AMIX struggles to sustain strong margins.

ROE > 15%
-239.36%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is AMIX Expensive or Cheap?

P/E Ratio

AMIX trades at -0.04 times earnings. This suggests potential undervaluation.

-0.04

PEG Ratio

When adjusting for growth, AMIX's PEG of -0.00 indicates potential undervaluation.

-0.00

Price to Book

The market values Autonomix Medical, Inc. at 0.26 times its book value. This may indicate undervaluation.

0.26

EV/EBITDA

Enterprise value stands at -0.51 times EBITDA. This is generally considered low.

-0.51

How Well Does AMIX Make Money?

Net Profit Margin

For every $100 in sales, Autonomix Medical, Inc. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $-2.39 in profit for every $100 of shareholder equity.

-2.39%

ROA

Autonomix Medical, Inc. generates $-2.20 in profit for every $100 in assets, demonstrating efficient asset deployment.

-2.20%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-20.51 in free cash annually.

$-20.51

FCF Yield

AMIX converts -7.20% of its market value into free cash.

-7.20%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.04

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.26

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.00

vs 25 benchmark

Current Ratio

Current assets to current liabilities

4.45

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-2.39

vs 25 benchmark

ROA

Return on assets percentage

-2.20

vs 25 benchmark

ROCE

Return on capital employed

-2.89

vs 25 benchmark

How AMIX Stacks Against Its Sector Peers

MetricAMIX ValueSector AveragePerformance
P/E Ratio-0.0429.53 Better (Cheaper)
ROE-239.36%497.00% Weak
Net Margin0.00%-11575.00% (disorted) Weak
Debt/Equity0.000.79 Strong (Low Leverage)
Current Ratio4.455.18 Strong Liquidity
ROA-219.93%-25.00% (disorted) Weak

AMIX outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Autonomix Medical, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ